Epsilogen is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.
Epsilogen has raised $16.3M in total funding. The most recent round was Series B. The last funding was announced in September 2024.
Epsilogen's investors include Schroders Capital, Epidarex Capital, Innovate UK, AlbionVC, 3B Future Health Fund.
Epsilogen is headquartered in London, United Kingdom.
Epsilogen is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.
Epsilogen is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Epsilogen — Funding & Investors." VCBacked, September 9, 2024, https://www.vcbacked.co/company/epsilogen. Accessed August 13, 2026.
VCBacked. (2024). Epsilogen — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/epsilogen
{{cite web |title=Epsilogen — Funding & Investors |url=https://www.vcbacked.co/company/epsilogen |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated